{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:42:27Z","timestamp":1760838147003,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bmc.2019.115227","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T20:14:42Z","timestamp":1576008882000},"page":"115227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254)"],"prefix":"10.1016","volume":"28","author":[{"given":"Bin","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander W.","family":"Hird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Bodnarchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Les","family":"Dakin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qibin","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Daly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Godin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen M.","family":"Hattersley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Brassil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"John Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Janetka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2019.115227_b0005","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1101\/gad.938601","article-title":"Hedgehog signaling in animal development: paradigms and principles","volume":"15","author":"Ingham","year":"2001","journal-title":"Genes Dev"},{"key":"10.1016\/j.bmc.2019.115227_b0010","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/nrd2086","article-title":"Targeting the Hedgehog pathway in cancer","volume":"5","author":"Rubin","year":"2006","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.bmc.2019.115227_b0015","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1016\/j.bmcl.2009.08.049","article-title":"GDC-0449 a potent inhibitor of the hedgehog pathway","volume":"19","author":"Robarge","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115227_b0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1021\/ml1000307","article-title":"Discovery of NVP- LDE225, a potent and selective smoothened antagonist","volume":"1","author":"Pan","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115227_b0025","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/cas.13285","article-title":"Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies","volume":"108","author":"Minami","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bmc.2019.115227_b0030","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1021\/ml2002423","article-title":"Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened","volume":"3","author":"Munchhof","year":"2012","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115227_b0035","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1158\/1078-0432.CCR-17-0723","article-title":"Phase I study of LY2940680, a Smo antagonist, in patients with advanced cancer including treatment-naive and previously treated basal cell carcinoma","volume":"24","author":"Bendell","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2019.115227_b0040","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/17460441.2014.920816","article-title":"Discovery and preclinical development of vismodegib","volume":"9","author":"Gould","year":"2014","journal-title":"Expert Opin Drug Discovery"},{"key":"10.1016\/j.bmc.2019.115227_b0045","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/OTT.S130910","article-title":"Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas","volume":"10","author":"Jain","year":"2017","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.bmc.2019.115227_b0050","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1038\/ncomms4309","article-title":"Lipidic cubic phase injector facilitates membrane protein serial femtosecond crystallography","volume":"5","author":"Weierstall","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2019.115227_b0055","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1038\/ncomms5355","article-title":"Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs","volume":"5","author":"Wang","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2019.115227_b0060","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nature18934","article-title":"Structural basis of Smoothened regulation by its extracellular domains","volume":"535","author":"Byrne","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2019.115227_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.04.029","article-title":"Structural basis of smoothened activation in hedgehog signaling","volume":"174","author":"Huang","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2019.115227_b0070","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1016\/j.bmcl.2012.04.104","article-title":"Discovery of novel hedgehog antagonists from cell-based screening: Isosteric modification of p38 bisamides as potent inhibitors of SMO","volume":"22","author":"Yang","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2019.115227_b0075","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature07275","article-title":"A paracrine requirement for hedgehog signalling in cancer","volume":"455","author":"Yauch","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2019.115227_b0080","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1541-7786.MCR-12-0022","article-title":"Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer","volume":"10","author":"Hwang","year":"2012","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.bmc.2019.115227_b0085","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1021\/j100588a021","article-title":"Intra- and intermolecular hydrogen bonding in chlorinated phenols and related compounds","volume":"79","author":"Levy","year":"1975","journal-title":"J Phys Chem"},{"key":"10.1016\/j.bmc.2019.115227_b0090","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1063\/1.464913","article-title":"Density-functional thermochemistry. III. The role of exact exchange","volume":"98","author":"Becke","year":"1993","journal-title":"J Chem Phys"},{"key":"10.1016\/j.bmc.2019.115227_b0095","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1021\/cr950066q","article-title":"Bioisosterism: A rational approach in drug design","volume":"96","author":"Patani","year":"1996","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmc.2019.115227_b0100","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1021\/jm1008924","article-title":"Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449)","volume":"54","author":"Giannetti","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115227_b0105","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1021\/jm3003697","article-title":"Methyl effects on protein-ligand binding","volume":"55","author":"Leung","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2019.115227_b0110","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/qua.24481","article-title":"Jaguar: A high-performance quantum chemistry software program with strengths in life and materials sciences","volume":"113","author":"Bochevarov","year":"2013","journal-title":"Int J Quantum Chem"},{"key":"10.1016\/j.bmc.2019.115227_b0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1747-0285.2005.00327.x","article-title":"Use of an induced fit receptor structure in virtual screening","volume":"67","author":"Sherman","year":"2006","journal-title":"Chem Biol Drug Des"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089619306686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089619306686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:05:40Z","timestamp":1760835940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089619306686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0968089619306686"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2019.115227","relation":{},"ISSN":["0968-0896"],"issn-type":[{"type":"print","value":"0968-0896"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254)","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2019.115227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115227"}}